{"product_id":"proteogenix-research-grade-olamkicept","title":"Research Grade Olamkicept","description":"\u003ch3\u003eIntroduction\u003c\/h3\u003e \u003cp\u003eOlamkicept is a novel biologic agent that has gained significant attention in the field of immunology. It is an antibody-based therapeutic that targets a specific protein, making it a promising treatment option for a variety of diseases. In this article, we will delve deeper into the structure, activity, and application of Research Grade Olamkicept.\u003c\/p\u003e \u003ch3\u003eStructure of Olamkicept\u003c\/h3\u003e \u003cp\u003eOlamkicept is an immunoglobulin G (IgG) antibody, specifically a human IgG1 kappa isotype. It is composed of two heavy chains and two light chains, each with a variable region and a constant region. The variable region is responsible for binding to its target, while the constant region determines its effector functions.\u003c\/p\u003e \u003cp\u003eThe target of Olamkicept is a protein known as B cell-activating factor (BAFF), which plays a crucial role in the survival and maturation of B cells. Olamkicept is designed to bind to and neutralize BAFF, thereby inhibiting its activity and reducing the number of B cells in circulation.\u003c\/p\u003e \u003ch3\u003eActivity of Olamkicept\u003c\/h3\u003e \u003cp\u003eThe activity of Olamkicept is primarily mediated through its binding to BAFF. By binding to BAFF, Olamkicept prevents it from interacting with its receptor on B cells, leading to the inhibition of B cell survival and maturation. This results in a decrease in the number of B cells, which are responsible for producing antibodies and contributing to autoimmune and inflammatory diseases.\u003c\/p\u003e \u003cp\u003eIn addition to its neutralizing activity, Olamkicept also has effector functions that can modulate the immune response. These include antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These mechanisms allow Olamkicept to target and eliminate cells that express BAFF, such as B cells and certain cancer cells.\u003c\/p\u003e \u003ch3\u003eApplication of Olamkicept\u003c\/h3\u003e \u003cp\u003eResearch Grade Olamkicept is currently being evaluated as a potential therapeutic for a wide range of diseases, including autoimmune disorders, B cell malignancies, and solid tumors. Some of the most promising applications of Olamkicept include:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eRheumatoid Arthritis (RA): BAFF is known to play a critical role in the development and progression of RA. By inhibiting BAFF, Olamkicept has shown promising results in reducing disease activity and improving symptoms in patients with RA.\u003c\/li\u003e \u003cli\u003eLupus: BAFF has also been implicated in the pathogenesis of systemic lupus erythematosus (SLE). Olamkicept has shown potential in reducing disease activity and improving biomarkers in patients with SLE.\u003c\/li\u003e \u003cli\u003eMultiple Myeloma (MM): BAFF is overexpressed in MM, and its inhibition has been shown to have anti-tumor effects. Olamkicept is being investigated as a potential treatment for MM, either as a monotherapy or in combination with other anti-cancer agents.\u003c\/li\u003e \u003cli\u003eNon-Hodgkin Lymphoma (NHL): BAFF is also involved in the survival and proliferation of B cell lymphomas, making it a promising target for Olamkicept. Early studies have shown positive results in patients with NHL, and further research is ongoing.\u003c\/li\u003e \u003c\/ul\u003e \u003ch3\u003eConclusion\u003c\/h3\u003e \u003cp\u003eOlamkicept is a promising biologic agent that has the potential to revolutionize the treatment of various diseases. Its unique structure and activity make it a highly specific and effective therapeutic for targeting BAFF, a key player in many autoimmune and inflammatory disorders. As research on Olamkicept continues, we can expect to see more applications and potential benefits of\u003c\/p\u003e\u003cp\u003eProteoGenix catalogue number PX-TA2018. For research use only.\u003c\/p\u003e\u003cp\u003eTarget: IL6; Host: Human; Clonality: Polyclonal Antibody.\u003c\/p\u003e\u003cp\u003eAvailable configurations: 50ug, 100ug, 1mg.\u003c\/p\u003e\u003cp\u003e\u003ca href=\"https:\/\/www.proteogenix.science\/wp-content\/uploads\/documents\/Datasheets\/PX-TA2018.pdf\"\u003eDownload the manufacturer datasheet\u003c\/a\u003e\u003c\/p\u003e","brand":"ProteoGenix","offers":[{"title":"50ug","offer_id":57357547045204,"sku":"ABM133819-1","price":124.0,"currency_code":"GBP","in_stock":true},{"title":"100ug","offer_id":57357547077972,"sku":"ABM133819-2","price":156.0,"currency_code":"GBP","in_stock":true},{"title":"1mg","offer_id":57357547110740,"sku":"ABM133819-3","price":519.2,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1040\/1782\/2036\/files\/sds-validation-1-research-grade-olamkicept_44a111de-e631-4be3-9567-c0c5e58dcbce.jpg?v=1790890703","url":"https:\/\/www.abmium.com\/fr\/products\/proteogenix-research-grade-olamkicept","provider":"ABMIUM","version":"1.0","type":"link"}